RAINIER is a multicenter, open-label, multi-cohort phase 1b/2 dose-optimization study enrolling adults aged 18 years or older ...

The study covered in this summary was published on ssrn.com as a preprint and has not yet been peer reviewed. Cytarabine plus an anthracycline has been the standard AML induction regimen for decades, ...

Treatment with BH-30236, a novel CLK inhibitor, was generally well tolerated as monotherapy and in combination with venetoclaxPreliminary ...

Patients with acute myeloid leukemia (AML) in remission for 3 years have survival rates similar to the general population, but long-term needs remain poorly understood. A retrospective analysis showed ...

IN8bio, Inc. announced that 100% of acute myeloid leukemia (AML) patients treated with its allogeneic gamma-delta T cell therapy, INB-100, remain in complete remission (CR) with a median follow-up of ...

"Our results demonstrate a consistent pattern of clinical activity and favorable safety across patients treated to date," ...

RNA expression-based risk stratification of de novo acute myeloid leukemia. Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1 mutated de novo acute myeloid ...